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Introduction: Rearrangements of RET are rare oncogenic
events in patients with non–small cell lung cancer (NSCLC).
While the characterization of Asian patients suggests a
predominance of nonsmokers of young age in this geneti-
cally deﬁned lung cancer subgroup, little is known about the
characteristics of non-Asian patients. We present the results
of an analysis of a European cohort of patients with RET
rearranged NSCLC.
Methods: Nine hundred ninety-seven patients with KRAS/
EGFR/ALK wildtype lung adenocarcinomas were analyzed
using ﬂuorescence in situ hybridization for RET fusions.
Tumor specimens were molecularly proﬁled and clinico-
pathological characteristics of the patients were collected.
Results: Rearrangements of RET were identiﬁed in 22 pa-
tients, with a prevalence of 2.2% in the KRAS/EGFR/ALK
wildtype subgroup. Co-occurring genetic aberrations were
detected in 10 patients, and the majority had mutations in
TP53. The median age at diagnosis was 62 years (range, 39–
80 years; mean ± SD, 61 ± 11.7 years) with a higher pro-
portion of men (59% versus 41%). There was only a slight
predominance of nonsmokers (54.5%) compared to current
or former smokers (45.5%).
Conclusions: Patients with RET rearranged adenocarci-
nomas represent a rare and heterogeneous NSCLC sub-
group. In some contrast to published data, we see a high
prevalence of current and former smokers in our white RET
cohort. The signiﬁcance of co-occurring aberrations, so far,
is unclear.
 2015 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. All rights reserved.
Keywords: Adenocarcinoma; Clinicopathological character-
istics; NSCLC; RET rearrangement; Smoking history; TP53Introduction
Despite advanced treatment options, non–small cell
lung cancer (NSCLC) is still the leading cause of cancer-
related death in the Western world. In recent years, a
growing number of therapeutically amenable geneticalterations have been identiﬁed, notably in patients with
lung adenocarcinomas (LADs). In particular, chromo-
somal rearrangements involving the anaplastic lym-
phoma kinase gene (ALK), c-ros oncogene 1 (ROS1), the
rearranged during transfection gene (RET), and most
recently the neuregulin 1 gene (NRG1) have been
described as rare oncogenic events in young adults with
either a history of no smoking or light smoking.1–4
Fusions of RET have long been known to have
oncogenic potential in patients with papillary thyroid
carcinomas.5 RET rearrangements were identiﬁed in 1%
of Asian patients with LAD and mostly involve KIF5B or
CCDC6.1–3 Activation of the fusion protein results in the
recruitment of oncogenic signalling cascades, such as the
phosphatidylinositol 3-kinase (PI3K)/AKT and RAS/
mitogen-activated protein kinase pathways (MAP/K).6
Successful targeted treatment of patients with RET
rearranged adenocarcinoma was published in preclinical
studies, case reports, and as preliminary data from a
phase II trial with cabozantinib (NCT01639508).7–9
Understanding the clinicopathological characteristics
of patients with rare genetic driver aberrations is
essential to reliably identify patients who might beneﬁt
from targeted therapies in a routine diagnostic setting. In
this retrospective study, we present the characteristics
of a European cohort of 22 patients with RET fused
LADs.
Methods
Patients and samples
This study was performed within the Network
Genomic Medicine (NGM), a collaborative health care
provider network for the molecular characterization and
personalized treatment of lung cancer (network center:
University Hospital Cologne, Germany), in collaboration
with the Lucerne Cantonal Hospital (Lucerne,
Switzerland), the University Hospital Innsbruck (Inns-
bruck, Austria), and the University Hospital Basel (Basel,
Switzerland). Lung adenocarcinomas and adenosqua-
mous carcinomas with wildtype sequences in KRAS,
ALK, and the sites of common EGFR mutations (EGFRdel19
and EGFRL858R) were tested for RET rearrangements
124 Michels et al Journal of Thoracic Oncology Vol. 11 No. 1using ﬂuorescence in situ hybridization (FISH). There
was no preselection regarding smoking history, age,
stage, or sex of the patients. Screening procedures were
conducted in accordance with the local ethical
guidelines.
RET FISH assay
For FISH, 2-mm tissue sections were hybridized with
ZytoLight SPEC RET Dual Color Break Apart Probes
(ZytoVision, Bremerhaven, Germany). The 30 RET probe
encompasses the kinase domain (i.e., 30 probe ZyGreen
and 50 probe ZyOrange labeling). Per case, 100 carci-
noma cells were evaluated. RET rearrangement criteria
for positivity: 20% (rearrangement fraction; University
Hospitals Cologne and Innsbruck) or 15% (Lucerne
Cantonal Hospital and University Hospital Basel) of cells
with aberrant patterns of either a break-apart of one or
both fusion signals into separated green and red signals
or of isolated green signals in addition to fusion signals.
Detection of co-occurring aberrations
Targeted massively parallel sequencing (MPS) was
performed at the University Hospital of Cologne on all
samples fromNGMand theUniversityHospital of Innsbruck
(N ¼ 18) on a MiSeq benchtop sequencer as described
previously (Illumina, San Diego, CA).10 The panel comprises
102 amplicons of 14 proto-oncogenes and tumor suppres-
sor genes, includingEGFR exons 18 to 21,KRAS (exons 2–3),
TP53 (exons 5–8), and BRAF (exons 11–15).
Sanger sequencing was performed at the Cantonal
Hospital of Lucerne and the University Hospital of Basel for
mutations in KRAS (exons 2–3), EGFR (exons 18–21),HER2
(exons 21–22), and BRAF (exons 11 and 15) on an ABIFigure 1. (A) Hematoxylin–eosin-stained micrograph of a lung a
signals of a dual color, break apart ﬂuorescent in situ hybridiz
rangement by separation of green and red signals (ZytoVision,Prism 3130 Genetic Analyzer (Applied Biosystems, Wal-
tham, MA). FISH was used for identiﬁcation of rearrange-
ments of ALK/ROS1 and ampliﬁcations of MET. Database
references included the International Agency for Research
on Cancer TP53 Database (available at http://p53.iarc.fr/
TP53GeneVariations.aspx), the Catalogue of Somatic Mu-
tations in Cancer (available at http://cancer.sanger.ac.uk/
cosmic), and the p53 Knowledgebase (available at http://
p53.bii.a-star.edu.sg/index.php).
Clinical characteristics
The clinical characteristics included age, sex, tumor
stage at diagnosis according to the Union for Interna-
tional Cancer Control classiﬁcation, smoking status, and
history of previous cancer therapies. Smoking status was
classiﬁed according to the 2008 US Centers for Disease
Control and Prevention criteria.11
Statistics
Qualitative variables were summarized by count and
percentage, quantitative variables by mean, standard
deviation (SD), median, and range. Distribution of time-to-
event, such as overall survival (OS) and follow-up period,
were described by the Kaplan–Meier estimator. The
overall prevalence of RET rearranged adenocarcinomas
refers to the prevalence in samples routinely analyzed
within NGM (August 2013 to February 2015; N ¼ 2616).
Results
Molecular characteristics
Tissue from 997 patients with KRAS-, EGFR-, and ALK-
negative tumors were screened by RET FISH (Fig. 1).denocarcinoma with RET rearrangement. (B) Image of merged
ation analysis of a lung adenocarcinoma revealing RET rear-
Bremerhaven, Germany).
Table 1. Clinical and molecular characteristics of patients with RET rearranged non–small cell lung cancer (N ¼ 22)
Patient
ID Sex
Age at
diagnosis
(y)
Initial
stage
(UICC)
Fraction of
RET rearranged
cells (%)
Additional genetic
aberrations
Smoking
history
Pack
years
No. of
systemic
treatments
Follow-up/
survival
(months)
01a F 53 I 34 None FS 20 0 13
02a M 66 III 87 None NS 0 2 47
03a F 56 III 100 CTNNB p.S33Y FS 5 2 100
04a M 47 IV 22 TP53 p.V157F S 40 2b 13
05a F 48 IV 23 TP53 p.V157F FS 24 3 17
06a M 80 IV 25 None NS 0 1 10
07a M 77 IV 27 None NS 0 2 8c
08a M 75 IV 87 None FS 90 1 18
09a M 49 III 21 TP53 p.R273H S 40 1 7c
10a F 39 IV 37 TP53 p.R181H NS 0 1 2c
11a M 76 II 31 MET low-level ampliﬁcation NS 0 0 5
12a F 51 III 27 TP53 p.G245C and EGFR p.L833F FS 25 3 17
13a M 57 IV 29 TP53 p.G244C NS 0 2b 10
14a M 61 III 34 None S 43 2 8
15 M 62 II 87 None NS 0 5b 62c
16 M 63 IV 47 None FS 5 4b 36c
17 F 53 II 65 None NS 0 0 24
18a F 69 II 49 None NS 0 2b 56
19a M 72 IV 77 TP53 p.S215N NS 0 5b 34c
20 M 43 III 40 None NS 0 2 16
21a F 74 IV 28 None NS 0 1 3
22a F 67 IV 77 TP53 p.I254fs*10 FS 45 2 8
aMassively parallel sequencing performed.
bHas received RET targeted therapy.
cDied.
F, female; FS, former smoker; M, male; NS, nonsmoker; S, smoker; UICC, Union for International Cancer Control.
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rearranged carcinomas (2.2%). The overall prevalence of
RET rearrangements within the MPS subgroup was
0.7%.
Co-occurring genetic aberrations were detected in 10
of 22 patients (45.5%; Table 1; Supplemental Fig. 1,
Supplemental Table 1). Eight patients had mutations in
TP53 (44.4%), of which seven were inactivating TP53
alterations. Of those, four were transversions (G > T). In
addition, we found a low level MET ampliﬁcation and a
gain of function mutation in CTNNB1 (CTNNB1S33Y) in
one patient each.12 Another patient’s tumor was found to
harbor a rare mutation in exon 21 of EGFR (EGFRL833F).
In our study, the slightly different deﬁnition of RET
positivity between the Swiss and German centers with
selection of either 15% or 20% as a threshold for RET
rearrangement had no inﬂuence on the overall results,
because in all of the Swiss cases >20% of tumor cells
had rearrangement signals.
Clinical characteristics
The median age at ﬁrst diagnosis was 62 years
(range, 39–80 years; mean ± SD, 61 ± 11.7 years), the
proportion of male sex was 59% (N ¼ 13) and of femalesex 41% (N ¼ 9; Table 2). Analysis of smoking status
revealed a slightly lower prevalence of history of tobacco
use (N ¼ 10; 45.5%) than of never smoking (N ¼ 12;
54.5%). Median quantity of pack-years within the cur-
rent and ever smoking group was 32.5 (range, 5–90
pack-years; mean ± SD, 33.7 ± 23.38 pack-years). We
have observed a higher proportion of inactivating TP53
mutations in patients with a history of smoking (N ¼ 5;
50%) than in patients with no smoking history (N ¼ 2;
16.7%; Fisher’s exact test: p ¼ 0.172 [data not shown]).
The distribution of stage at the time of initial diagnosis
was 23% (n ¼ 5) for stage I and II and 77% (n ¼ 17) for
stage III and IV. Of the 11 stage IV patients, only two
initially suffered from distant metastases in more than
one anatomical region (i.e., the contralateral lung, brain,
adrenal glands, liver, or bone). All other patients had
single organ/tissue metastases, and only four patients
had extrathoracic metastatic lesions (36%; Table 2).
Nineteen patients had received at least one line of
systemic antineoplastic treatment (86.4%). The median
OS for patients with stage IV disease was 34 months (SD,
18.8 months; mean ± SD, 29.3 ± 4.3 months;
Supplemental Fig. 2). The median OS for all stages’ pa-
tients was not met during the median follow-up period
Table 2. Clinical characteristics of patients with RET
rearranged non–small cell lung cancer (N ¼ 22)
Characteristics No. %
Age at ﬁrst diagnosis (y) 22 100
Mean ± SD 61 ± 11.7
Median (range) 62 (39–80)
Sex
Female 9 41
Male 13 59
Smoking history
Never 12 54.6
Former 7 31.8
Current 3 13.6
UICC stage
I 1 5
II 4 18
III 6 27
IV 11 50
Location of metastases (stage IV) 11 50
Lung 2 18
Pleura 5 45
Bone 2 18
CNS 2 18
Adrenal gland 3 27
Liver 2 18
CNS, central nervous system; SD, standard deviation; UICC, Union
for International Cancer Control.
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[data not shown]).
Discussion
To our knowledge, this is the largest study published
so far analyzing rearrangements of RET in white patients
with LADs. Cohorts of similar size have been described in
Asian patient populations.1–3 In line with the prevalence
described in these studies, we have detected RET rear-
rangements in 0.7% of patients with adenocarcinomas.
Likewise, no signiﬁcant difference was seen in the age
distribution between Asian and white cohorts (median,
62 years and 57.5 years versus 62 years, respectively).2,3
In contrast to the ﬁndings in Asian patients, the fre-
quency of history of tobacco use was substantially higher
in our RET cohort (45.5% versus 18.2–31.8%).1–3 These
ﬁndings question the practice of preselecting patients
for RET FISH analysis based on smoking history. Sup-
porting our results, single cases of white patients with RET
rearrangements and smoking history have been reported.8
Of the 11 stage IV patients, only four had extra-
thoracic organ metastases. This pattern resembles that
found in patients with KRAS-mutated NSCLC and seems
to be different, for instance, from that seen in patients
with ALK-fused NSCLC.13
The median overall survival in the stage IV subgroup
was 34 months (SD, 18.8 months; mean ± SD, 29.2 ± 4.3
months; Supplemental Fig. 1). Retrospective analyses ofgenetically unselected patients found a median OS of
approximately 18 months in patients who were inoper-
able.14 However, because of the small number of patients
in our analysis, the impact of RET rearrangements on the
prognosis needs to be interpreted with care.
Six of the patients described herein have received
RET-targeted therapy (Table 1). For one of these pa-
tients, a partial response under treatment with vande-
tanib has been published.8 Two of these patients were
treated in the Cologne center with cabozantinib without
a clinical response. Two additional patients received
more than one putative RET inhibitor, but there is only
fragmentary information on clinical efﬁcacy. All other
patients were treated with chemotherapy only. More
patients receiving RET inhibitor therapy are necessary to
draw any conclusions on the impact of such a targeted
therapy on the survival of these patients.
We found a high frequency of co-occurring genetic
aberrations in our RET cohort (N ¼ 10; 45.5%). Missense
and nonsensemutations in TP53 leading to inactivation of
the protein were by far the most frequent events in the
samples analyzed by MPS (N¼ 18; Table 2). Interestingly,
within the group of patients with smoking history, mu-
tations in TP53 were more frequent than in patients with
no history of smoking. However, because of the small
patient numbers, this effect was statistically nonsigniﬁ-
cant. Recently, a transcriptome meta-analysis of 753
NSCLC specimens revealed a greater average number of
fusions in tumorswithmissense or nonsensemutations in
TP53 as compared to tumors with wildtype TP53.15 These
ﬁndings suggest an essential role of TP53 alterations in
RET-driven carcinogenesis of lung cancer. In addition, we
detected a low-level ampliﬁcation of MET in one patient.
Whether low-level ampliﬁcations of MET are targetable
oncogenic aberrations, however, is questionable. The
same counts for the rare missense mutation of exon 21 of
the EGFR gene (EGFRL833F) detected in a 51-year-old
woman with a history of smoking. For the gain of function
mutation in the beta-catenin gene (CTNNB1S33Y), a
transforming potential has been discussed in T-cell ma-
lignancies.12 In this context, it also has to be noted that
according to the diagnostic algorithm that we used to
select patients for RET FISH analyses, RET rearrangement
status of patients with activating KRAS or common EGFR
mutation is unknown. Overall, our observations do not
argue for a mutually exclusive occurrence of RET rear-
rangements and suggest routine testing for other muta-
tions besides RET in these patients.
In summary, our data also show that white patients
with RET rearranged NSCLC represent a heteroge-
neous subgroup with regard to smoking history and
co-occurring mutations. Screening for RET rearrange-
ments should not exclude patients with a history of to-
bacco use.
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